22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...
22 June 2022 - Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan demonstrated superior progression-free and ...
21 June 2022 - Phase 2b study in MAB pulmonary infections on-going and enrolling as planned. ...
14 June 2022 - Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR ...
22 June 2022 - Medicare’s drug program could have saved up to $3.6 billion in 2020 by mirroring the pricing ...
21 June 2022 - Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (Qulipta) in adult patients ...
21 June 2022 - Citing the need to inspect a third-party contract packaging manufacturer, the U.S. FDA has issued a complete ...
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using tebentafusp ...
20 June 2022 - Application based on Phase 3 TRANSFORM study in which Breyanzi outperformed the current standard of care ...
21 June 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
20 June 2022 - The US FDA eliminated its backlog of overdue domestic pre-approval inspections, yet such progress has been ...
20 June 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
15 June 2022 - HIRA has been analysing how new reimbursements for anti-diabetic combination therapies mixing oral SGLT-2 and DPP-4 ...
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
20 June 2022 - Lessons learned from international collaboration on observational research during the pandemic were highlighted during the latest global ...
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...